Find company announcements below, or check out the latest news in the right side menu.
25. October 2012
Sales growth in DKK was 6% (2% LCY, 3% organic) compared with the first 9 months of 2011. EBIT grew by 12%, and the EBIT margin increased to 24.6%. The expectations for full-year 2012 EBIT growth, EBIT margin and net profit growth are maintained, as is the expectation for free cash flow.
19. October 2012
On January 20, 2012, Novozymes initiated a share buyback program in accordance with the provisions of European Commission Regulation no. 2273/2003 of December 22, 2003, also referred to as the Safe Harbour Regulation.
12. October 2012
5. October 2012
28. September 2012
21. September 2012
14. September 2012
12. September 2012
Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has decreased its holding of B shares in Novozymes to 7.64%, previously reported at 7.82% (a decrease of 0.18%).
7. September 2012
31. August 2012
24. August 2012
17. August 2012
16. August 2012
Sales growth in DKK was 7% (3% LCY, 3% organic) compared with the first half of 2011. EBIT grew by 12%, and the EBIT margin increased to 24.2%. The expectation for full-year 2012 EBIT growth is increased to 11-14% from 9-12%, and EBIT margin is now expected at 23-24%.
10. August 2012
3. August 2012
27. July 2012
Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has increased its holding of B shares in Novozymes to 7.82%, previously reported at 7.71% (an increase of 0.11%).
20. July 2012
13. July 2012
6. July 2012
29. June 2012
22. June 2012
15. June 2012
8. June 2012
1. June 2012
25. April 2013
1. April 2013
| Copyright © 2010 Novozymes. All Rights Reserved.